Plus Therapeutics, Inc. (PSTV)
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
$9.43M
Dr. Marc H. Hedrick M.D.
14.00
Austin, TX
Aug 09, 2000
-0.52
$-3.09
1.04
1.10
-733.97%
-0.39
0.05
2.25
3.98
1.05
-114.87%
-423.52%
Similar stocks (15)
Immix Biopharma, Inc.
IMMX
Protara Therapeutics, Inc.
TARA
NeuroBo Pharmaceuticals, Inc.
NRBO
Surrozen, Inc.
SRZN
Monopar Therapeutics Inc.
MNPR
Vaccinex, Inc.
VCNX
Hoth Therapeutics, Inc.
HOTH
Palisade Bio, Inc.
PALI
Enveric Biosciences, Inc.
ENVB
Avenue Therapeutics, Inc.
ATXI
Revelation Biosciences, Inc.
REVB
Dermata Therapeutics, Inc.
DRMA
Quoin Pharmaceuticals, Ltd.
QNRX
Aditxt, Inc.
ADTX
Panbela Therapeutics, Inc.
PBLA
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (15)
Immix Biopharma, Inc.
IMMX
Protara Therapeutics, Inc.
TARA
NeuroBo Pharmaceuticals, Inc.
NRBO
Surrozen, Inc.
SRZN
Monopar Therapeutics Inc.
MNPR
Vaccinex, Inc.
VCNX
Hoth Therapeutics, Inc.
HOTH
Palisade Bio, Inc.
PALI
Enveric Biosciences, Inc.
ENVB
Avenue Therapeutics, Inc.
ATXI
Revelation Biosciences, Inc.
REVB
Dermata Therapeutics, Inc.
DRMA
Quoin Pharmaceuticals, Ltd.
QNRX
Aditxt, Inc.
ADTX
Panbela Therapeutics, Inc.
PBLA
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%